Some eight months after its launch, companies are still not using England’s £340m ($407m) Innovative Medicines Fund (IMF) to get their new non-cancer drugs to patients because it carries too much risk, says Sean Richardson, vice-president and general manager for the UK and Ireland at Alexion Pharmaceuticals Inc..
England’s Innovative Medicines Fund Needs De-Risking To Make It Work
The Innovative Medicines Fund is not delivering the ambition that was set out when it was launched in England last year, according to one UK company general manager.
